Venous Thromboembolism in Cancer Patients: Guideline Update

The American Society of Hematology presents guidelines for the management of cancer-associated thrombosis.

Sponsoring Organization: American Society of Hematology (ASH)

Background and Objective

Venous thromboembolism (VTE) is prevalent in patients with solid and hematological malignancies and contributes to morbidity and mortality. Standard management includes low molecular-weight heparin (LMWH) and direct oral anticoagulants (DOACs) but is complicated by higher bleeding rates than in patients with VTE without cancer. A panel convened by ASH presents updated recommendation on prophylaxis and management of VTE in cancer patients.

Key Points

Primary prophylaxis with a DOAC is suggested for patients receiving systemic therapy who are perceived to have high (rather than low or intermediate) risk for thrombosis. Also suggested is that patients with m…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Venous Thromboembolism in Cancer Patients: Guideline Update

Topics

Reviewing Author